

21 Sept 2022

To Whom It May Concern:

Seagen Inc. is committed to the disclosure of clinical trial results conducted in the EU & EEA per the requirements of Commission Guideline 2012/C 302/03. The trial listed below was registered with the EudraCT database but was not initiated / was withdrawn prior to enrollment of any EU participants.

Please consider this as notice to close this EudraCT record:

EudraCT#	Study Title	Sponsor Code	Sponsor Name
2019-003983-28	A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)	SGN35-028	Seagen Inc.